14 results about "Marijuana plant" patented technology

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The present disclosure provides a film for enhancing the growth of plants in the Cannabaceae family, the film being capable of blocking solar spectrum in the range 430-550 nm. The present disclosure also provides a single- or multi-layer plastic greenhouse film for enhancing cannabis plant growth, where the single- or multi-layer plastic greenhouse film (a) has at least one blue light blocking layer for blocking solar spectrum in the range of 430-500 nm; (b) has a high transmittance for red light in the solar spectrum in the range of 600-750 nm.

A mechanism for monitoring cannabis and predicting or determining a harvesting time. A sensing arrangement generates a temporal sequence of VOC values, each representing a measured amount of a first set of one or more volatile organic compounds (VOCs) in the air surrounding some cannabis. This temporal sequence is then processed to determine a harvesting time, at which the cannabis is ready for harvesting (e.g., meets some predetermined criteria for achieving a harvesting goal).

This document describes methods and compositions for preventing hermaphroditism in Cannabis plants, as well as methods and compositions for making male sterile Cannabis plants.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.

There is provided a method for enhanced extraction of cannabis oil from a cannabis plant material, and a free-flowing powder consisting of particles of cannabis plant material for use in such method for enhanced extraction. The cannabis plant material is characterized by a cannabis strain and a cannabis plant part. The method comprising a step of comminuting said cannabis plant material to a powder of a preselected particle size distribution (PSD) characterized by 10≤Dv(90)≤100 μm as determined by laser diffraction particle size analysis prior to extraction process. The PSD is preselected in accordance with said cannabis strain and said plant part.

Described herein are methods of treatment of metabolic syndrome using Cannabis Plant Material to reduce fasting glucose and insulin and lower the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index to mitigate metabolic syndrome and associated Type II Diabetes, Coronary Heart Disease, and Stroke, pharmacological compounds for same and methods for making the pharmacological compounds.

The unique annual herbaceous Cannabis plant variety ‘ESB-1’ is provided. The variety can be distinguished by its outstanding features of a THCV cannabinoid content ratio of about 1 part THC to 1 part THCV and purple leaf stem, when grown under certain growing conditions.

Exemplary embodiments described herein include cannabis females that have a potential to form male reproductive parts that may be treated in a manner to affect the gibberellic acid pathway to prevent the formation of male reproductive parts. Additionally, cannabis females may be treated with exogenous compounds (sprays, chemicals, etc.) to reduce the amount of gibberellic acid produced.

Provided herein is the identification of markers and genes associated with hermaphroditism susceptibility and resistance in Cannabis. The markers are useful for breeding Cannabis plants having resistance to hermaphroditism, and methods for selecting plants by obtaining nucleic acids and detecting one or more markers that indicate resistance to hermaphroditism to establish plant lines having such resistance are provided.

Homogeneous extract-infused cannabis biomasses, methods for their preparation, and products produced therefrom, such as pre-rolled joints, are provided. An exemplary method comprises steps of providing a cannabis extract; heating the cannabis extract; providing a milled cannabis plant material; applying the heated cannabis extract to the milled cannabis plant material using a predefined ratio of the cannabis plant material to the heated cannabis extract to provide an extract-applied plant material; and mixing the extract-applied plant material to provide a homogeneous extract-infused cannabis biomass, wherein there is less than a 15% variability in a target concentration of the at least one biomass cannabinoid, the at least one biomass terpene, or any combination thereof throughout a prepared batch and / or between alternate batches of the homogeneous extract-infused cannabis biomass.

The invention relates to a small-scale delivery system of a nutrient solution for increasing inflorescences and cannabinoid yield of cannabis plants and a method thereof, wherein the nutrient solution is a water solution of saccharides in their preferred amounts, while other nutrients can be optionally present. The delivery system comprises at least one container filled with the nutrient solution, a dosing device and infusion means. The dosing device pushes the solution out of the container and into the cannabis plant through the infusion means over a determined time period. The method according to the invention uses plant stem infusion for delivery of the nutrient solution into cannabis plants via a defined flow regime. The cannabinoid yield in the cannabis plant increased up to 34 wt.% compared control plants.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.

System for controlling the growth and flowering phases of autoflowering cannabis plants, comprehensive - a sensor unit for recording environmental parameters, - a control unit for processing sensor data, - a lighting unit with adjustable spectral distribution, - an irrigation unit characterized in that the control unit contains a switching module which can trigger a one-time targeted light intervention to make the transition from the vegetative growth phase to the flowering phase controllable.